不用本金就能赚钱的方法

来宝网Logo

热门词:生物显微镜 水质分析仪 微波消解 荧光定量PCR 电化学工作站 生物安全柜

现在位置不用本金就能赚钱的方法>技术资料不用本金就能赚钱的方法>行业动态>公司动态>德国Evotec收购药物开发Kinaxo

德国Evotec收购药物开发Kinaxo

Evotec2011年2月10日 11:16 点击:1797

   德国Evotec 德国KINAXO Biotechnologies GmbH公司

不用本金就能赚钱的方法 德国Evotec收购Kinaxo

· Adds propriEtary Technologies for response prediction and Drug efficacy and safety assessment; especially in Key indication area oncology

 

·  Adds fast growing business with an expected revenue of € 2.5m in 2011

· Initial PURCHASE PRICE of approx € 12m consists of € 3M in cash and 2.6m SHARES; plus earn-out payments of up to € 4m Dependent On Performance milestoneS

Hamburg, Germany - 9 February 2011: 不用本金就能赚钱的方法Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX) today announced the signing of a definitive agreement to acquire all shares in Kinaxo Biotechnologies GmbH, a Munich-based drug discovery alliance company supporting the development of targeted drugs.

Strengthening  Evotec's position as quality leader in drug discovery

不用本金就能赚钱的方法The acquisition of Kinaxo confirms Evotec's leading position as fully integrated drug discovery and early development partner for pharma and biotechnology companies. Integration of Kinaxo's novel technologies enables Evotec and its partners to take earlier educated decisions on drug efficacy, safety and response in patients.

Kinaxo's capabilities comprise a unique combination of innovative technologies improving drug development across the entire pharma value chain:

 

-       Cellular Target Profiling® uncovers the molecular targets of compounds with unknown mode-of-action and reveals possible off-target side effects early in the discovery and development process.

-       KinAffinity®不用本金就能赚钱的方法 determines the cellular selectivity of kinase inhibitors, which represent the most important class of targeted cancer drugs.

-       PhosphoScout® provides valuable knowledge on drug modes-of-action in vivo不用本金就能赚钱的方法 and how they respond to drug treatment. 

"Through the acquisition of Kinaxo, Evotec gains access to a highly innovative technology base in drug discovery, which allows us to integrate a powerful response prediction platform with our leading drug discovery expertise. We are proud to significantly strengthen our performance-based discovery offering to our customers with this unique value proposition," said Dr Werner Lanthaler, Chief Executive Officer of Evotec AG. "

Dr. Andreas Jenne, CEO of Kinaxo, adds: "We are excited to join forces with Evotec. Our technology portfolio perfectly fits into Evotec's integrated service offering. This will allow us to fully leverage our capabilities and grow our business much faster within larger discovery alliances." 

Prof. Dr. Axel Ullrich, Director of the Max-Planck-Institute for Biochemistry, Martinsried, and co-founder of Kinaxo commented: "Kinaxo has built a unique technology platform that allows comprehensive analysis of cancer signal transduction processes and their response to drug treatment. The integration of the leading drug discovery capability will implement Evotec as a driver towards personalised medicine in the future."

Transaction structure reflects value potential

 

不用本金就能赚钱的方法The purchase price consists of a cash consideration of € 3m and 2.597.400 shares from authorised capital. In addition an earn-out component of up to € 4m in cash will become due if certain performance-based milestones are reached. Parts of the shares are held in escrow and their release is subject to certain company events and representations. All shares issued are subject to certain lock-up provisions. The deal is expected to close in April 2011.

Despite cash requirements for transaction and integration costs of approx. € 4m resulting from the acquisition, Evotec confirms to keep a very strong strategic cash balance also in 2011. For the current fiscal year, the Company expects to grow revenues by more than 15% and to end the year 2011 with a liquidity of more than € 64 m.

不用本金就能赚钱的方法Evotec invites you to join a conference call announcing the acquisition of Kinaxo.

Details of the Conference Call:

不用本金就能赚钱的方法Thursday 10 February 2011 at

不用本金就能赚钱的方法8.30 a.m. CET

不用本金就能赚钱的方法7.30 a.m. GMT/2.30 a.m. US Time (East Coast)

Dial-in Numbers:

Europe:

+49 (0) 6958 999 0805 (Germany)
+44 (0) 207 153 2027 (UK)
不用本金就能赚钱的方法 US: +1 480 629 9724

Pass Code:  4407349

A simultaneous slide presentation for participants dialing in via phone is available at , password: evotec0211.

You can also listen to the conference call via audio webcast including presentation slides at www.evotec.com.

If you are unable to attend, a recording will be available for 24 hours after the call at the following phone numbers: +49 (0) 69 58 99 90 568 (Germany), +44 (0) 20 7959 6720 (UK), +1 303 590 3030 (US). The access code is 4407349#. The on-demand version of the webcast will be available on our website: www.evotec.com - Investors/Events/Financial Calendar.

 

Contact: Dr Werner Lanthaler, Chief Executive Officer,Evotec AG, Tel.: +49.(0)40.56081-242,  werner.lanthaler@evotec.com

(来源: Evotec )


全年征稿 / 资讯合作

联系邮箱:kefu@strauss-usa.com

BANQUANYUMIANZESHENGMING

  • 凡本网注明“来源:来宝网”的所有作品,版权均属于来宝网,转载请必须注明来宝网, http://strauss-usa.com,违反者本网将追究相关法律责任。
  • 本网转载并注明自其它来源的作品,目的在于传递更多信息,并不代表本网赞同其观点或证实其内容的真实性,不承担此类作品侵权行为的直接责任及连带责任。其他媒体、网站或个人从本网转载时,必须保留本网注明的作品来源,并自负版权等法律责任。
  • 如涉及作品内容、版权等问题,请在作品发表之日起一周内与本网联系,否则视为放弃相关权利。


湖南快乐十分 湖南快乐十分 福建快3走势图0 福建快3走势图 河南快3走势图 河南快3走势图 广东11选5开奖结果 福建11选5走势图